Mechanical Thrombectomy
DeviceTreatment of LVO with mechanical thrombectomy
NCT Number: NCT03845491
The purpose of this Registry is to assess the procedural success and clinical outcomes associated with various operator techniques for mechanical thrombectomy in large vessel occlusions (LVO).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Ghent University Hospital, Ghent, Belgium
ASSIST is a prospective, global, consecutive enrollment Registry of anterior circulation acute ischemic stroke patients with an LVO who undergo treatment with one of the interventional techniques using Stryker Neurovascular devices for the first pass. The purpose of this Registry is to assess the procedural success and clinical outcomes associated with various operator techniques for mechanical thrombectomy in large vessel occlusions (LVO) in the anterior circulation. Data will be collected on the use of Stryker market-released neurovascular mechanical access and mechanical thrombectomy devices that are commercially available or that may be approved for commercial use during the conduct of the Registry. This Registry will also collect data, including time-to-treatment and quality of life measures, to allow for subset analyses.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The subject is participating in another device trial or any other clinical trial where the study procedure or treatment might confound this study's endpoint.
Treatment of LVO with mechanical thrombectomy
Time frame: 90 Days (±14 days)
This measure assesses clinical outcome using the Modified Rankin Scale (mRS). Modified Rankin Scale measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is a score ranging from 0-6 with the following degree of disability: 0 = No symptoms at all; no limitations and no symptoms; 1 = No significant disability, 2 = Slight disability; 3 = Moderate disability; 4 = Moderate severe disability, 5 = Severe disability; 6= Death. The lower mRS Score indicates less disability, and higher score indicates increased disability.
Time frame: At the time of procedure, after the first pass
This outcome measures percentage of subjects who achieved complete reperfusion after the first pass, defined by eTICI score of 2c or greater. Independent Imaging Core Lab adjudicated the outcome using the Expanded Treatment in Cerebral Infarction (eTICI) scale. The higher eTICI score indicates successful revascularization.
The Expanded TICI (eTICI) Perfusion Score Categories are:
Time frame: 90 Days (±14 days)
Percentage of subjects with an excellent functional outcome of mRS of 0-1 at Day 90 (± 14).
Modified Rankin Scale measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is a score ranging from 0-6 with the following degree of disability: 0 = No symptoms at all, no limitations and no symptoms; 1 = No significant disability, 2 = Slight disability; 3 = Moderate disability; 4 = Moderate severe disability, 5 = Severe disability; 6= Death. The lower mRS Score indicates less disability.
Time frame: Discharge/ Day 5-7 (Whichever is earlier)
Percentage of subjects with an "early response" at Discharge/Day5-7 (whichever is earlier) defined as a NIHSS drop of ≥10 points from baseline or NIHSS score of 0 or 1.
NIHSS (National Institutes of Health Stroke Scale) is an assessment to objectively quantify the impairment caused by a stroke. It is composed of 11 items, each of which scores a specific ability. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.
Time frame: Day 90 (±14 days)
The Euro Quality of Life Questionnaire - 5 Level 5D Version (EQ5D5L) is composed of 5 dimensions- mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is evaluated by the subject on 5 level scale: no problems, slight problems, moderate problems, severe problems and extreme problems. The outcome reported shows severe and extreme levels were combined and only 4 levels are reported.
Time frame: At the time of procedure, after the first pass, and at the end of the procedure
This outcome reports percentage of subjects who achieved eTICI 2b50, eTICI 2b67, eTICI 2c,or eTICI 3 on first pass after primary technique used and at the end of the endovascular procedure.
Independent Imaging Core Lab adjudicated the outcome using the Expanded Treatment in Cerebral Infarction (eTICI) scale. The higher eTICI score indicates successful revascularization.
The Expanded TICI (eTICI) Perfusion Score Categories are:
Time frame: During the procedure, from groin puncture to after the first pass
This outcome measures overall time (in minutes) observed from groin puncture to the specific eTICI reperfusion score at end of first pass for treatment of target occlusion. Each subject can only be in one eTICI category and therefore they are mutually exclusive.
Independent Imaging Core Lab adjudicated the outcome using the Expanded Treatment in Cerebral Infarction (eTICI) scale. The higher eTICI score indicates successful revascularization.
The Expanded TICI (eTICI) Perfusion Score Categories are:
Time frame: Time of procedure, from groing puncture to revascularization
This outcome measures the overall time (in minutes) observed from groin puncture to final reperfusion of eTICI 2c or 3 for treatment of target occlusion.
Independent Imaging Core Lab adjudicated the outcome using the Expanded Treatment in Cerebral Infarction (eTICI) scale. The higher eTICI score indicates successful revascularization.
The Expanded TICI (eTICI) Perfusion Score Categories are:
Time frame: 90 Days (+/- 14 Days)
Prespecified safety outcome measures include all-cause mortality and stroke-related mortality up to 90 days (±14), device and/or procedure related SAEs up to 90 Days (±14), neurological deterioration at 24 hours post procedure, embolization to new territory adjudicated by core lab. and neurological deterioration at 24 hours post-procedure to 48 hours
Stryker Neurovascular
Industry
ASSIST Registry to Assess the Procedural Success and Clinical Outcomes Associated With Various Operator Techniques for Mechanical Thrombectomy in Large Vessel Occlusions (LVO).
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05416853
Arterial Occlusive Diseases, Brain Diseases
Hefei, Anhui, China
View Trial DetailsNCT07709806
Brain Diseases, Cardiovascular Diseases
Siping, Jilin, China
View Trial DetailsNCT07654582
Brain Diseases, Cardiovascular Diseases
Cairo, Egypt
View Trial DetailsNCT06049498
Brain Diseases, Cardiovascular Diseases
Beijing, China
View Trial Details